



Concert Pharmaceuticals to Participate in Fireside Chat at Jefferies London Healthcare Conferences

November 11, 2021

LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 11, 2021-- [Concert Pharmaceuticals, Inc.](#) (NASDAQ: CNCE) today announced that it will participate in a virtual fireside chat at The Jefferies London Healthcare Conference. The on-demand fireside chat will be available beginning at 8:00 a.m. GMT on November 18, 2021.

A webcast of the Jefferies fireside chat may be accessed in the [Investors](#) section of the Company's website at www.concertpharma.com. A replay of the webcast will be available on Concert's website for two weeks following the presentation.

About Concert

[Concert Pharmaceuticals](#) is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its [DCF Platform](#)[®] (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead [product candidate](#) is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates. For more information please visit www.concertpharma.com or follow us on Twitter at [@ConcertPharma](#) or on [LinkedIn](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20211111005218/en/>

Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com

Source: Concert Pharmaceuticals, Inc.